热门资讯> 正文
继第一季度业绩粗略后，Editas Medicine下跌9%
2024-05-08 22:44
- Editas Medicine (NASDAQ:EDIT) is down ~9% in Wednesday morning trading after reporting disappointing Q1 results in which the company missed on both lines.
- In the quarter, Editas' net loss widened ~26% year over year to ~$62M. Net loss per share, basic and diluted, was -$0.76 compared to -$0.71 in the year-ago period.
- The company was hurt in the quarter by a massive ~88% decline in revenue to $1.14M. Also, total operating expenses rose ~12% year over year to ~$68.1M.
- At the end of the quarter (March 31), Editas (EDIT) had cash, cash equivalents, and marketable securities of $376.8M compared to $427.1M on Dec. 31, 2023.
- The company noted that its financial runway will allow operations to continue through at least 2026.
More on Editas Medicine
- Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
- Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
- Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)
- Editas Medicine Q1 2024 Earnings Preview
- Editas, Bristol Myers extend T cell therapy collaboration
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
